目的 分析北京大學腫瘤醫(yī)院紫杉醇治療乳腺癌時發(fā)生的不良反應，提高對紫杉醇的認識，以便更好地發(fā)揮紫杉醇的治療作用。方法 回顧并分析2014年7月-2016年12月北京大學腫瘤醫(yī)院上報的81例紫杉醇治療乳腺癌的不良反應。結果 發(fā)生紫杉醇不良反應的乳腺癌患者年齡以50～59歲居多，發(fā)生時間基本出現(xiàn)在輸注30 min內(nèi)，不良反應主要癥狀為胸悶憋氣（88.89%）、骨髓抑制（77.78%）、皮膚瘙癢（33.33%）和血壓下降（33.33%）。51例為首次輸注，16例發(fā)生不良反應的患者有過敏史。結論 應用紫杉醇化療的乳腺癌患者先進行預處理方案及試驗量輸注，可減少不良反應發(fā)生。患者輸注過程中應密切關注，出現(xiàn)不良反應積極對癥處理。

Objective To improve the recognization of paclitaxel and achieve a better therapeutic effect, the adverse reactions of paclitaxel in treatment of breast cancer in Peking University Cancer Hospital were analyzed. Methods Adverse reactions (81 cases) induced by paclitaxel in treatment of breast cancer were reviewed and analyzed, which were reported from July 2014 to December 2016 in Peking University Cancer Hospital. Results Most patients with adverse reactions induced by paclitaxel in treatment of breast cancer were 50-59 years old. Adverse reactions mainly occurred in 30 min during infusion. The main symptoms of adverse reactions were chest tightness and dyspnea (88.89%), bone marrow suppression (77.78%), skin itching (33.33%), and decreased blood pressure (33.33%). Patients (51 cases) were first infusion of paclitaxel. There were 16 cases of patients with history of allergies. Conclusion Patients with paclitaxel-containing chemotherapy should be given pretreatment and infusion with a tested dose, which could reduce the incidence of adverse reactions. The patients should be paid attention to adverse reactions closely, and the management according to the symptoms should be performed during the infusion.